Keywords: Mylan, Shionogi, CIMA, Orapred, Endocrine and neoplastic conditions, Patent challenge

Mylan sued by Shionogi and CIMA over Orapred patent challenge

Article | 20 December 2010

Print This

US generics major Mylan (Nasdaq: MYL) has confirmed that, along with its subsidiary Mylan Pharmaceuticals, it been sued by Japanese ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in